QuantiFERON®-TB Gold test in the identification of latent tuberculosis infection in immigrants

SummaryBackgroundThe identification and treatment of latent tuberculosis infection (LTBI) among immigrants are an effective strategy for TB control in developed countries. A new test for LTBI identification that uses more specific antigens of Mycobacterium tuberculosis is now commercially available under the brand name of QuantiFERON®-TB Gold test.ObjectiveTo compare QuantiFERON®-TB Gold test to tuberculin skin testing (TST) for the detection of LTBI among immigrants from high endemic TB areas.Patients and methodsUndocumented immigrants attending a district medical center were enrolled if they originated from high endemic TB areas, the time of arrival in Italy was ≤5 years, had neither active TB disease nor known immunodeficiency status. The TST was applied according to standards and QuantiFERON®-TB Gold test was performed following the manufacturer's instructions.ResultsHundred subjects were included in the comparative analysis. TST was positive in 44% of subjects; 15% had a positive QuantiFERON®-TB Gold test result. The total agreement between TST and QuantiFERON®-TB Gold test was 71%, for a κ statistics of 0.37; agreement was 100% for TST negative results, but only 34% for TST positive ones. In the multivariate logistic regression analysis, previous BCG vaccination was independently associated with a lower chance of disagreement between the tests.ConclusionThe prevalence of LTBI among immigrants was lower when determined by QuantiFERON®-TB Gold; this may be a consequence of more specific MTB antigens used. Our results suggest that QuantiFERON®-TB Gold may be used as confirmatory test for TST positive immigrants candidate to preventive therapy.